NervGen Net Income Per Share vs Capex To Depreciation Analysis

NGEN Stock

CAD 2.79 0.01 0.36%

NervGen Pharma financial indicator trend analysis is infinitely more than just investigating NervGen Pharma Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NervGen Pharma Corp is a good investment. Please check the relationship between NervGen Pharma Net Income Per Share and its Capex To Depreciation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Income Per Share vs Capex To Depreciation

Net Income Per Share vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NervGen Pharma Corp Net Income Per Share account and Capex To Depreciation. At this time, the significance of the direction appears to have almost identical trend.

The correlation between NervGen Pharma's Net Income Per Share and Capex To Depreciation is 0.98. Overlapping area represents the amount of variation of Net Income Per Share that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of NervGen Pharma Corp, assuming nothing else is changed. The correlation between historical values of NervGen Pharma's Net Income Per Share and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income Per Share of NervGen Pharma Corp are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Net Income Per Share i.e., NervGen Pharma's Net Income Per Share and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Income Per Share

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most indicators from NervGen Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NervGen Pharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to drop to about 4.9 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year

NervGen Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Common Stock Shares Outstanding	Total Liab	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Other Liab	Net Debt	Cash And Short Term Investments	Net Receivables	Other Current Assets	Other Stockholder Equity	Capital Stock	Intangible Assets	Common Stock	Property Plant And Equipment Net	Property Plant Equipment
Total Assets		0.66	0.66	0.72	0.94	-0.82	0.84	0.85	0.77	-0.32	0.84	0.66	-0.32	0.72	0.7	-0.32	-0.93	0.85	0.43	0.46	0.87	0.94	-0.79	0.87	0.78	0.68
Other Current Liab	0.66		1.0	-0.04	0.66	-0.95	0.6	0.69	0.52	-0.84	0.87	1.0	-0.84	-0.04	-0.07	-0.84	-0.86	0.93	0.83	0.27	0.9	0.81	-0.69	0.92	0.87	0.99
Total Current Liabilities	0.66	1.0		-0.04	0.66	-0.95	0.6	0.7	0.54	-0.85	0.87	1.0	-0.85	-0.04	-0.07	-0.85	-0.86	0.93	0.84	0.29	0.9	0.81	-0.69	0.92	0.86	0.99
Total Stockholder Equity	0.72	-0.04	-0.04		0.64	-0.22	0.55	0.48	0.53	0.32	0.29	-0.03	0.32	1.0	1.0	0.32	-0.45	0.28	-0.19	0.36	0.35	0.5	-0.47	0.32	0.22	-0.01
Net Tangible Assets	0.94	0.66	0.66	0.64		-0.85	0.64	0.84	0.81	-0.37	0.86	0.66	-0.37	0.64	0.61	-0.37	-0.92	0.86	0.56	0.46	0.89	0.96	-0.68	0.88	0.67	0.64
Retained Earnings	-0.82	-0.95	-0.95	-0.22	-0.85		-0.63	-0.81	-0.69	0.76	-0.92	-0.95	0.76	-0.22	-0.19	0.76	0.95	-0.98	-0.82	-0.38	-0.99	-0.93	0.79	-0.99	-0.83	-0.93
Accounts Payable	0.84	0.6	0.6	0.55	0.64	-0.63		0.76	0.62	-0.2	0.67	0.61	-0.2	0.55	0.54	-0.2	-0.73	0.66	0.26	0.52	0.65	0.73	-0.68	0.67	0.85	0.67
Non Current Assets Total	0.85	0.69	0.7	0.48	0.84	-0.81	0.76		0.97	-0.44	0.77	0.71	-0.44	0.48	0.44	-0.44	-0.8	0.77	0.61	0.59	0.81	0.85	-0.7	0.82	0.7	0.69
Non Currrent Assets Other	0.77	0.52	0.54	0.53	0.81	-0.69	0.62	0.97		-0.32	0.63	0.54	-0.32	0.53	0.5	-0.32	-0.67	0.64	0.55	0.62	0.71	0.75	-0.62	0.7	0.5	0.5
Other Assets	-0.32	-0.84	-0.85	0.32	-0.37	0.76	-0.2	-0.44	-0.32		-0.52	-0.85	1.0	0.32	0.34	1.0	0.59	-0.74	-0.9	-0.18	-0.7	-0.48	0.6	-0.73	-0.48	-0.79
Common Stock Shares Outstanding	0.84	0.87	0.87	0.29	0.86	-0.92	0.67	0.77	0.63	-0.52		0.87	-0.52	0.29	0.26	-0.52	-0.93	0.92	0.63	0.25	0.91	0.96	-0.6	0.91	0.9	0.88
Total Liab	0.66	1.0	1.0	-0.03	0.66	-0.95	0.61	0.71	0.54	-0.85	0.87		-0.85	-0.03	-0.06	-0.85	-0.86	0.93	0.84	0.29	0.9	0.81	-0.69	0.92	0.86	0.99
Deferred Long Term Liab	-0.32	-0.84	-0.85	0.32	-0.37	0.76	-0.2	-0.44	-0.32	1.0	-0.52	-0.85		0.32	0.34	1.0	0.59	-0.74	-0.9	-0.18	-0.7	-0.48	0.6	-0.73	-0.48	-0.79
Net Invested Capital	0.72	-0.04	-0.04	1.0	0.64	-0.22	0.55	0.48	0.53	0.32	0.29	-0.03	0.32		1.0	0.32	-0.45	0.28	-0.19	0.36	0.35	0.5	-0.47	0.32	0.22	-0.01
Net Working Capital	0.7	-0.07	-0.07	1.0	0.61	-0.19	0.54	0.44	0.5	0.34	0.26	-0.06	0.34	1.0		0.34	-0.43	0.26	-0.22	0.33	0.32	0.47	-0.45	0.29	0.2	-0.03
Other Liab	-0.32	-0.84	-0.85	0.32	-0.37	0.76	-0.2	-0.44	-0.32	1.0	-0.52	-0.85	1.0	0.32	0.34		0.59	-0.74	-0.9	-0.18	-0.7	-0.48	0.6	-0.73	-0.48	-0.79
Net Debt	-0.93	-0.86	-0.86	-0.45	-0.92	0.95	-0.73	-0.8	-0.67	0.59	-0.93	-0.86	0.59	-0.45	-0.43	0.59		-0.98	-0.64	-0.33	-0.97	-0.97	0.8	-0.97	-0.85	-0.86
Cash And Short Term Investments	0.85	0.93	0.93	0.28	0.86	-0.98	0.66	0.77	0.64	-0.74	0.92	0.93	-0.74	0.28	0.26	-0.74	-0.98		0.76	0.32	0.99	0.93	-0.8	0.99	0.84	0.92
Net Receivables	0.43	0.83	0.84	-0.19	0.56	-0.82	0.26	0.61	0.55	-0.9	0.63	0.84	-0.9	-0.19	-0.22	-0.9	-0.64	0.76		0.48	0.75	0.62	-0.55	0.78	0.49	0.77
Other Current Assets	0.46	0.27	0.29	0.36	0.46	-0.38	0.52	0.59	0.62	-0.18	0.25	0.29	-0.18	0.36	0.33	-0.18	-0.33	0.32	0.48		0.36	0.42	-0.44	0.4	0.26	0.26
Other Stockholder Equity	0.87	0.9	0.9	0.35	0.89	-0.99	0.65	0.81	0.71	-0.7	0.91	0.9	-0.7	0.35	0.32	-0.7	-0.97	0.99	0.75	0.36		0.95	-0.84	1.0	0.8	0.88
Capital Stock	0.94	0.81	0.81	0.5	0.96	-0.93	0.73	0.85	0.75	-0.48	0.96	0.81	-0.48	0.5	0.47	-0.48	-0.97	0.93	0.62	0.42	0.95		-0.74	0.95	0.84	0.81
Intangible Assets	-0.79	-0.69	-0.69	-0.47	-0.68	0.79	-0.68	-0.7	-0.62	0.6	-0.6	-0.69	0.6	-0.47	-0.45	0.6	0.8	-0.8	-0.55	-0.44	-0.84	-0.74		-0.83	-0.62	-0.69
Common Stock	0.87	0.92	0.92	0.32	0.88	-0.99	0.67	0.82	0.7	-0.73	0.91	0.92	-0.73	0.32	0.29	-0.73	-0.97	0.99	0.78	0.4	1.0	0.95	-0.83		0.82	0.91
Property Plant And Equipment Net	0.78	0.87	0.86	0.22	0.67	-0.83	0.85	0.7	0.5	-0.48	0.9	0.86	-0.48	0.22	0.2	-0.48	-0.85	0.84	0.49	0.26	0.8	0.84	-0.62	0.82		0.91
Property Plant Equipment	0.68	0.99	0.99	-0.01	0.64	-0.93	0.67	0.69	0.5	-0.79	0.88	0.99	-0.79	-0.01	-0.03	-0.79	-0.86	0.92	0.77	0.26	0.88	0.81	-0.69	0.91	0.91

Click cells to compare fundamentals

NervGen Pharma Account Relationship Matchups

NervGen Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.8M	6.7M	17.9M	23.9M	13.2M	11.3M
Other Current Liab	172.4K	583.3K	725.5K	8.1M	11.7M	12.3M
Total Current Liabilities	923.9K	755.1K	1.1M	10.2M	15.1M	15.9M
Total Stockholder Equity	5.8M	5.9M	16.8M	13.5M	(2.0M)	(1.9M)
Net Tangible Assets	5.3M	5.4M	16.3M	13.0M	15.0M	7.7M
Retained Earnings	(11.1M)	(22.3M)	(35.0M)	(55.8M)	(78.2M)	(74.2M)
Accounts Payable	751.6K	171.8K	352.5K	2.0M	550.4K	672.0K
Cash	4.1M	5.6M	16.9M	22.5M	11.7M	9.9M
Non Current Assets Total	509.6K	473.4K	475.8K	726.7K	720.5K	555.8K
Common Stock Shares Outstanding	25.9M	32.1M	39.3M	52.6M	59.6M	41.5M
Liabilities And Stockholders Equity	6.8M	6.7M	17.9M	23.9M	27.5M	28.8M
Total Liab	923.9K	755.1K	1.1M	10.4M	15.2M	16.0M
Net Invested Capital	5.8M	5.9M	16.8M	13.5M	(2.0M)	(1.9M)
Total Current Assets	6.3M	6.2M	17.4M	23.1M	12.5M	10.7M
Net Working Capital	5.3M	5.4M	16.3M	12.9M	(2.6M)	(2.5M)
Net Debt	(4.1M)	(5.6M)	(16.9M)	(22.2M)	(20.0M)	(19.0M)
Cash And Short Term Investments	4.1M	5.6M	16.9M	22.5M	25.8M	27.1M
Net Receivables	122.5K	62.6K	64.0K	27.0K	250.2K	262.7K
Other Current Assets	2.0M	540.8K	427.6K	669.9K	602.9K	594.4K
Other Stockholder Equity	1.7M	5.3M	9.5M	11.8M	13.6M	14.3M
Accumulated Other Comprehensive Income	1.7M	5.3M	9.5M	11.8M	13.6M	14.3M
Capital Stock	15.3M	22.9M	42.4M	57.4M	58.9M	36.8M
Intangible Assets	509.6K	471.4K	473.2K	431.4K	520.8K	393.9K
Common Stock	15.3M	22.9M	42.4M	57.4M	66.0M	69.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for NervGen Stock Analysis

When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC